

INFORME DE BÚSQUEDA DE PATENTES				
N° de solicitud: 14000880				
CRITERIOS PARA LA BÚSQUEDA (anexar pantallazo o reporte en PDF, junto con los boléanos utilizados**)				
Palabras clave utilizadas		PHARMACEUTICAL COMPOSITION; AMIDE DERIVATIVE; INHIBITING THE GROWTH OF CANCER CELLS; NON-METALLIC SALT LUBRICANT; SUCROSE FATTY ACID ESTERS,		
CLASIFICACIONES UTILIZADAS PARA LA BÚSQUEDA		CIP: A01N 25/16. CPC (Opcional):		
DOCUMENTOS CONSIDERADOS RELEVANTES (documentos patentes, literatura no patente, etc...)				
Informes/Base de datos	N° de solicitud/ Autor*	Fecha de Publicación/ Presentación (DD/MM/AAAA)	Reiv. afectadas (con indicación, si procede, de las partes relevantes)	Categoría especiales de los documentos citados**
ORBIT, EPOQUENET, ESPACENET, USPTO	US2010179120	15/Julio/2010	1 a 6 NIVEL INVENTIVO	Y
	WO2005105050	10/Noviembre/2005	1 a 6 NIVEL INVENTIVO	Y
** Categorías especiales de documentos citados:				
“A” documento que define el estado general de la técnica no considerado como particularmente relevante. “E” solicitud de patente o patente anterior pero publicada en la fecha de presentación internacional o en fecha posterior. “P” documento publicado antes de la fecha de presentación internacional pero con posterioridad a la fecha de prioridad reivindicada.		“X” documento particularmente relevante; la invención reivindicada no puede considerarse nueva o que implique una actividad inventiva por referencia al documento aisladamente considerado. “Y” documento particularmente relevante; la invención reivindicada no puede considerarse que implique una actividad inventiva cuando el documento se asocia a otro u otros documentos de la misma naturaleza, cuya combinación resulta evidente para un experto en la materia.		

Literatura no patente *Se incluye entre otros, toda la referencia de la literatura no patente.	
Fecha del reporte de búsqueda:	02/11/2018

ESPACENET

Documents cited:	Search	[Y]» WO2008150118 (HANMI PHARM IND CO LTD [KR], et al) [Y] 1-16 * page 88; example 36 * * Preparation example 1; pages 102-103 *;
		[AP]» WO2011155793 (HANMI HOLDINGS CO LTD [KR], et al) [AP] 1-16 * the whole document *
		[Y] - Anonymous, Handbook of Pharmaceutical Excipients, Pharmaceutical Press, (2006), XP002736604 [Y] 1-16 * page 767 *
		[Y] - Anonymous, The Merck Index, Merck&Co., Inc., (2001), XP002736605 [Y] 1-16 * item 5675; page 5682 *
	International search	[A]» KR101013319B (HANMI PHARM. CO., LTD.);
		[A]» KR20050104152 (CHOI SEUNG HO [KR])

USPTO

uspto

Patents Trademarks Fees and payment Help MyUSPTO

Public Patent Application Information Retrieval

Patent eBusiness

Patent Application Information Retrieval

Global Dossier Order Certified Application As Filed Order Certified File Wrapper View Order List

14/124,436 PHARMACEUTICAL COMPOSITION COMPRISING AMIDE DERIVATIVE INHIBITING THE GROWTH OF CANCER CELLS AND NON-METALLIC SALT LUBRICANT 32002/50583

Select New Case Application Data Transaction History Image File Wrapper Patent Term Adjustments Continuity Data Foreign Priority Fees Published Documents Address & Attorney/Agent Supplemental Content Assignments Display References

This application is officially maintained in electronic form. To View: Click the desired Document Description. To Download and Print: Check the desired document(s) and click Start Download.

Available Documents

Mail Room Date	Document Code	Document Description	Document Category	Page Count	PDF
07-26-2017	ISSUE.NTF	Issue Notification	PROSECUTION	1	☐
07-11-2017	FWCLM	Index of Claims	PROSECUTION	1	☐
07-11-2017	OA.APPENDIX	Office Action Appendix	PROSECUTION	5	☐
07-11-2017	IIFW	Issue Information including classification, examiner, name, claim, renumbering, etc.	PROSECUTION	3	☐
06-21-2017	IFEE	Issue Fee Payment (PTO-85B)	PROSECUTION	1	☐
06-21-2017	WFEE	Fee Worksheet (SB06)	PROSECUTION	2	☐
06-21-2017	N417	EFS Acknowledgment Receipt	PROSECUTION	2	☐
05-25-2017	ANE.I	Amendment After Final or under 37CFR 1.312, initiated by the examiner.	PROSECUTION	1	☐

Patent Information

Patent Searches

Other

Patent Guidance and General Info

Codes, Rules & Manuals

Employee & Office Directories

Resources & Public Notices

Patent Official Gazette

Search Patents & Applications

Search Biological Sequences

Copies, Products & Services

Copyrights

Trademarks

Policy & Law

Reports

ORBIT

Menu Explorer

Patent family searches (FamPat)

Search Step	Result(s)	Query	Assistant	Source	Action
10	7	9 AND 5	Search history	FAMPAT	Show results Modify Save Alert Delete
9	150	7 AND 6	Search history	FAMPAT	Show results Modify Save Alert Delete
8	0	4 AND 7	Search history	FAMPAT	Show results Modify Save Alert Delete
7	2576	(SUCROSE S FATTY S ACID S ESTERS)/BI/SA/IN/PA	Easy search	FAMPAT	Show results Modify Save Alert Delete
6	213806	(PHARMACEUTICAL S COMPOSITION)/BI/SA/IN/PA	Easy search	FAMPAT	Show results Modify Save Alert Delete
5	52488	(CANCER S CELLS)/BI/SA/IN/PA	Easy search	FAMPAT	Show results Modify Save Alert Delete
4	1864	(NON_METALLIC AND SALT AND LUBRICANT)/BI/SA/KEYWIN/PA	Easy search	FAMPAT	Show results Modify Save Alert Delete
3	34	((NEPRILYSIN OR "NEUTRAL ENDOPEPTIDASE") AND INHIBIT)/TI/AB/IIW/CLMS AND PD <= 2015-02-11	Advanced search	FAMPAT	Show results Modify Save Alert Delete
2	27	((HERBICIDE)/TI/AB/IIW/CLMS AND (+METHANAMINIUM)/DESC/ODES AND (FURAN+)/DESC/ODES)	Advanced search	FAMPAT	Show results Modify Save Alert Delete
1	41	((HERBICIDE)/TI/AB/IIW/CLMS AND (+METHANAMINIUM)/DESC/ODES)	Advanced search	FAMPAT	Show results Modify Save Alert Delete

Easy search Filter Explorer

7 results for 9 AND 5 - Collection: FAMPAT

#	Title	Publication number	1st app. date	Applicant/Assignee	Relevanc	Litigation
1	Sustained release preparation of a macrolide compound like tacrolimus	WO9949863	1999-03-25	ASTELLAS PH...	100 %	
2	Cancer drug and uses	CA2898113	2014-01-14	BIOCOEPA; HE...	86 %	
3	Interferon gamma conjugates	WO200136001	2000-11-13	MAKSIDZHEN ...	85 %	
4	Gene relating to saccharide metabolism or lipid metabolism	WO03093470	2003-04-28	SANKYO*	73 %	
5	Compounds useful as protein kinase inhibitors	WO2008076392	2007-12-14	VERTEX PHAR...	16 %	
6	Compounds useful as protein kinase inhibitors	WO2008060597	2007-11-15	VERTEX PHAR...	15 %	
7	Thiophene-carboxamides useful as inhibitors of protein kinases	WO2007139816	2007-05-23	VERTEX PHAR...	12 %	

Preview Image

Sustained release preparation of a macrolide compound like tacrolimus

EPOQUENET



New connection on: : 20-07-2018 : 00:55:28 - Last disconnection on: : 19-07-2018 : 22:12:43

V 4.0.0.44358(LP,U,linux) (Rev:43856 2017-04-27 09:03:29 +0200W(D201802)) (RPM D201802)

Welcome to EPOQUE Rebuild under the Production Environment

[EPODOC: SS 1] ..FI

Select a database: ..FI EPODOC

+ Database: EPODOC

[EPODOC: SS 1] SUCROSE AND FATTY AND ACID AND ESTERS

Results in EPODOC 686

[SS 2] NON-METALLIC AND SALT AND LUBRICANT

Results in EPODOC 0

EPODOC: term 'NON-METALLIC' not found in index 'BI'. WARNING(1)

[SS 3] NON AND METALLIC AND SALT AND LUBRICANT

Results in EPODOC 52

[SS 4] 3 AND 1

Results in EPODOC 0

[SS 5] 1 AND POORLY AND ABSORBED

Results in EPODOC 5

[SS 6] ..li pn ti ab



1/5 © EPODOC / EPO

PN - [US2013171248](#) A1 20130704

TI - ORAL FORMULATION FOR DELIVERY OF **POORLY ABSORBED DRUGS**

AB - A composition for oral delivery of a **poorly absorbed** drug is disclosed. The composition includes the drug, an enhancer for increasing absorption of the drug through the intestinal mucosa, a promoter, which further increases the absorption of the drug in the presence of the enhancer, and optionally a protector for protecting the drug from physical or chemical decomposition or inactivation in the gastrointestinal tract. Illustrative enhancers include **sucrose fatty acid esters**, and illustrative promoters include aminosugars and amino **acid** derivatives, such as poly(amino acids). Illustrative protectors include methylcellulose, poly(vinyl alcohol), and poly(vinyl pyrrolidone).

2/5 © EPODOC / EPO

PN - [US2011045029](#) A1 20110224

TI - ORAL FORMULATION FOR DELIVERY OF **POORLY ABSORBED DRUGS**

AB - A composition for oral delivery of a **poorly absorbed** drug is disclosed. The composition includes the drug, an enhancer for increasing absorption of the drug through the intestinal mucosa, a promoter, which further increases the absorption of the drug in the presence of the enhancer, and optionally a protector for protecting the drug from physical or chemical decomposition or inactivation in the gastrointestinal tract. Illustrative enhancers include **sucrose fatty acid esters**, and illustrative promoters include aminosugars and amino **acid** derivatives, such as poly(amino acids). Illustrative protectors include methylcellulose, poly(vinyl alcohol), and poly(vinyl pyrrolidone).

3/5 © EPODOC / EPO

PN - [WQ2005105050](#) A1 20051110

TI - ORAL FORMULATION FOR DELIVERY OF **POORLY ABSORBED DRUGS**

AB - A composition for oral delivery of a **poorly absorbed** drug is disclosed. The composition includes the drug, an enhancer for increasing absorption of the drug through the intestinal mucosa, a promoter, which alone does not increase absorption of the drug through the intestinal mucosa, but which further increases the absorption of the drug in the presence of the enhancer, and optionally a protector for protecting the drug from physical or chemical decomposition or inactivation in the gastrointestinal tract. Illustrative enhancers include **sucrose fatty acid esters**, and illustrative promoters include aminosugars and amino **acid** derivatives, such as poly(amino acids). Illustrative protectors include methylcellulose, poly(vinyl alcohol), and poly(vinyl pyrrolidone).

4/5 © EPODOC / EPOPN - [US2006088592](#) A1 20060427

TI - (A1 B2)

Oral formulation for delivery of **poorly absorbed** drugs

AB - (A1 B2)

A composition for oral delivery of a **poorly absorbed** drug is disclosed. The composition includes the drug, an enhancer for increasing absorption of the drug through the intestinal mucosa, a promoter, which alone does not increase absorption of the drug through the intestinal mucosa, but which further increases the absorption of the drug in the presence of the enhancer, and optionally a protector for protecting the drug from physical or chemical decomposition or inactivation in the gastrointestinal tract. Illustrative enhancers include **sucrose fatty acid esters**, and illustrative promoters include aminosugars and amino **acid** derivatives, such as poly (amino acids). Illustrative protectors include methylcellulose, poly(vinyl alcohol), and poly(vinyl pyrrolidone).

5/5 © EPODOC / EPOPN - [MXPA06012489](#) A 20070208TI - ORAL FORMULATION FOR DELIVERY OF **POORLY ABSORBED** DRUGS.

AB

A composition for oral delivery of a **poorly absorbed** drug is disclosed. The composition includes the drug, an enhancer for increasing absorption of the drug through the intestinal mucosa, a promoter, which alone does not increase absorption of the drug through the intestinal mucosa, but which further increases the absorption of the drug in the presence of the enhancer, and optionally a protector for protecting the drug from physical or chemical decomposition or inactivation in the gastrointestinal tract. Illustrative enhancers include **sucrose fatty acid esters**, and illustrative promoters include aminosugars and amino **acid** derivatives, such as poly (amino acids). Illustrative protectors include methylcellulose, poly(vinyl alcohol), and poly(vinyl pyrrolidone).